Eton Pharmaceuticals Inc(ETON) Price Forecast & Company Analysis. P/E · Dividend · Earnings · Price Target · RSI · MACD | US Stocks Today
September 25 at 7:30 PM ET (Korea 9/26 08:30)
Full metrics table
| Index | RUT | P/E | 152.51 | EPS (ttm) | 0.38 | Insider Own | 4.9% | Shs Outstand | 28.3M | Perf Week | 3.93% |
| Market Cap | 1.65B | Forward P/E | 27.47 | EPS next Y | 93.1% | Insider Trans | -29.99% | Shs Float | 27.2M | Perf Month | -7.89% |
| Enterprise Value | 1.65B | PEG | 0.26 | EPS next Q | 0.31 | Inst Own | 69.65% | Short Float | 5.68% | Perf Quarter | 61.57% |
| Income | 0.01B | P/S | 15.61 | EPS this Y | 210.71% | Inst Trans | 9.34% | Short Ratio | 2.72 | Perf Half Y | 145.97% |
| Sales | 0.11B | P/B | 35.03 | EPS next 5Y | 107.4% | ROA | 11.67% | Short Interest | 1.54M | Perf YTD | 241.1% |
| Book/sh | 1.65 | P/C | 61.43 | EPS past 3/5Y | 21.89% 33.66% | ROE | 35.97% | 52W High | -13.09% ($66.37) | Perf Year | 186.4% |
| Cash/sh | 0.94 | P/FCF | 111.93 | Sales past 3/5Y | 55.53% 359.57% | ROIC | 19.01% | 52W Low | 304.2% ($14.27) | Perf 3Y | 1127.23% |
| Dividend Est. | - | EV/EBITDA | 78.44 | EPS Y/Y TTM | 399.54% | Gross Margin | 57.87% | Volatility(W/M) | 5.81% 4.77% | Perf 5Y | 1051.3% |
| Dividend TTM | - | EV/Sales | 15.64 | Sales Y/Y TTM | 81.49% | Oper. Margin | 15.63% | ATR (14) | 3 | Perf 10Y | - |
| Dividend Ex-Date | - | Quick Ratio | 1.3 | EPS Q/Q | 467.43% | Profit Margin | 12.02% | RSI (14) | 52.96 | Recom | 1 |
| Dividend Gr. 3/5Y | - | Current Ratio | 1.52 | Sales Q/Q | 98.59% | SMA20 | -0.62% ($58.04) | Beta | 0.88 | Target Price | $71 |
| Payout | - | Debt/Eq | 0.63 | Earnings | 2026/8/13 | SMA50 | 8.11% ($53.35) | Rel Volume | 0.91 | Prev Close | $59.49 |
| Employees | 44 | LT Debt/Eq | 0.43 | EPS/Sales Surpr. | 84.4% 38.67% | SMA200 | 85.26% ($31.13) | Avg Volume(3M) | 0.57M | Price | $57.68 |
| IPO | 2018/11/13 | Option/Short | Yes/Yes | Trades | 7742 | Volume | 514,396 | Change | -3.04% |
💊 Eton Pharmaceuticals (ETON) is a US-based specialty pharmaceutical company focused on rare diseases. The company concentrates on directly commercializing treatments for ultra-rare diseases with small patient populations in the US, and holds a portfolio of multiple commercial products along with a late-stage development pipeline in the pediatric, metabolic, and endocrine areas.
Over the past 1 year, on the higher side
13% below its 1-year high.
Traded about as much as usual That is 91% of its average volume.
ETON makes money exceptionally well
Of every $100 in sales, $15.63 is kept as operating profit.
Tap to view numbers
Earnings are growing steadily
Earnings are expected to grow by +210.7% this year.
Tap to view numbers
However, it looks expensive
Counting its debt, for $100 of yearly operating cash you would pay $7,844. Peers typically go for $1,031.
Tap to view numbers
Results have missed expectations
Frequently misses analyst estimates
Tap to view numbers
The outlook is positive
Analyst sentiment is Strong Buy.
Tap to view numbers
Holding long would have paid off
Bought 5 years ago, your return today would be +1051.3%. The S&P 500 did +74% over the same period.
Tap to view numbers
No dividend
It reinvests profits in the business instead of paying dividends.
Ownership looks stable
Institutions hold 69.7%.
Tap to view numbers
Multiple ETFs hold this stock, but only a sliver
Buying this ETF gives you exposure to this stock as well.
It ranks #29 of 83 in the industry
Based on market cap of $2B.
FAQ
What kind of company is ETON?
ETON belongs to the Healthcare sector and operates in the Drug Manufacturers - Specialty & Generic industry.
What is the market cap of ETON?
The market cap of ETON is approximately $1.6B, ranking 2,247 within its sector.
What is the P/E ratio of ETON?
ETON has a P/E ratio of approximately 152.5x, which can be used to assess its valuation relative to the Healthcare sector average.
What is the 52-week high and low for ETON?
ETON has recorded a 52-week high of $66.37 and a low of $14.27.
